Attend the Premier Forum which Shapes the Law, Policy, and Proceedings of Paragraph IV Litigation.
Our 2023 Event has Concluded
2023’s Members of the Judiciary
Honorable Leonard P. Stark
United States Judge
U.S. Court of Appeals for the Federal Circuit
(Former Chief Judge, United States District Court, District of Delaware)
Honorable Stanley R. Chesler
District Judge
United States District Court, District of New Jersey
Honorable Maryellen Noreika
District Judge
United States District Court, District of Delaware
Honorable Mitchell Goldberg
District Judge
United States District Court, Eastern District of Pennsylvania
(Visiting Judge, District of Delaware)
Honorable Joshua Wolson
District Judge
United States District Court
Eastern District of Pennsylvania
(Visiting Judge, District of Delaware)
Honorable Christopher J. Burke
Magistrate Judge
District of Delaware
2023 Government Representatives from U.S. Patent and Trademark Office
Honorable Jacqueline Bonilla
Deputy Chief Administrative Patent Judge, Patent Trial & Appeal Board
U.S. Patent and Trademark Office
Honorable Susan Mitchell
Lead Judge, Patent Trial & Appeal Board
U.S. Patent and Trademark Office
Honorable Grace Obermann
Administrative Patent Judge, Patent Trial & Appeal Board
U.S. Patent and Trademark Office
2023 Co-Chairs
Honorable Kathleen M. O’Malley (Ret.)
Of Counsel
Irell & Manella LLP
(Former United States Circuit Judge
U.S. Court of Appeals for the Federal Circuit)
Neema Kumar
Vice President, IP, North America
Sandoz
Serena Farquharson Torres
Executive Director, Assistant General Counsel
Bristol Myers Squibb
“This year’s Paragraph IV Disputes conference comes at an important time. Our innovation and IP Ecosystem are under attack from a variety of sources, putting our economy, the future of our health care, and our strategic place in the world at risk. I look forward to discussing these risks and possible ways to minimize those risks with the talented pool of IP professionals the conference annually brings together.
I am also personally pleased that I am being given the chance to conduct a dialogue with Judge Leonard Stark, my successor on the Federal Circuit. That will be a highlight of the Conference for me.”
— Honorable Kathleen M. O’Malley (Ret.)
“A robust and predictable patent system is critical to incentivizing innovation while facilitating access and ensuring the long-term sustainability of lower cost critical medicines. Join industry leaders, members of the judiciary, key agency representatives and your colleagues as we discuss game changing legislation impacting our industry and patients, current Hatch-Waxman trends, pharmaceutical policy initiatives and much more.”
— Neema Kumar
“Being on the forefront of pioneering research makes me both excited and hopeful for our patients yet somehow uncertain of the future protection of such innovation. I’m looking forward to hearing from government agencies, the judiciary, in-house and outside counsel regarding various considerations impacting the future of patent procurement as well as patent enforcement.”
— Serena Farquharson Torres
A REVIEW OF ACI’s PARAGRAPH IV DISPUTES CONFERENCES
3,700+
Attendees
560+
Speakers
110+
Sponsors
DISTINGUISHED FACULTY
The best that the bar, the bench, and the industry have to offer
MASTER LEVEL STRATEGIES
For litigators and in-house counsel
UNPARALLELED CONNECTIONS
With the “Who’s Who” of Hatch-Waxman litigators
Join the conference that the “who’s who” of Hatch-Waxman litigators have designated as the forum which sets the standards for Paragraph IV practice.
Since 2006, when we launched our inaugural conference, pharmaceutical patent practitioners from throughout the country and in some instances across the globe have attended this conference to confer with each other and assess the implications and imprimaturs of court cases, legislation, and industry behaviors which affect the patent endgame and the pursuit of related profits. They also come to hear from Judges — both from the federal judiciary, and U.S. P.T.O.’s PTAB — the FTC, and the FDA.
Leaders from both brand and generic drug companies recognize that this event is the single forum which serves both sides of the industry and is second to none in offering both legal and economic “take aways” for every sphere of this costly, complex and evolving litigation. This is the only event on market which not only addresses the hot topics, but also puts them within the context of pre-suit considerations, case filings, final adjudication and every step in between. This unique dynamic exemplifies not only the importance of the content and legal theory presented, but the contending business acuities as well.
We invite you to join us at this flagship event to get caught up on legal developments and learn how your peers (and opponents) are navigating the ever-changing landscape.
